Sanofi SA (NYSE:SNY) announced an annual dividend on Tuesday, February 13th, Wall Street Journal reports. Shareholders of record on Thursday, May 10th will be paid a dividend of 1.8609 per share on Monday, June 4th. This represents a dividend yield of 4.72%. The ex-dividend date of this dividend is Wednesday, May 9th. This is a boost from Sanofi’s previous annual dividend of $1.58.
Sanofi has decreased its dividend payment by an average of 4.9% annually over the last three years. Sanofi has a dividend payout ratio of 49.7% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Sanofi to earn $3.64 per share next year, which means the company should continue to be able to cover its $1.64 annual dividend with an expected future payout ratio of 45.1%.
Shares of Sanofi (NYSE:SNY) traded down $0.19 on Tuesday, hitting $39.40. The company’s stock had a trading volume of 3,410,426 shares, compared to its average volume of 2,541,867. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt-to-equity ratio of 0.26. The firm has a market cap of $98,288.38, a P/E ratio of 10.82, a PEG ratio of 2.04 and a beta of 0.85. Sanofi has a twelve month low of $38.14 and a twelve month high of $50.65.
An institutional investor recently raised its position in Sanofi stock. State Street Corp raised its position in Sanofi SA (NYSE:SNY) by 401.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,183 shares of the company’s stock after acquiring an additional 32,967 shares during the quarter. State Street Corp’s holdings in Sanofi were worth $1,972,000 as of its most recent SEC filing. 9.07% of the stock is owned by institutional investors.
A number of analysts recently issued reports on the company. Sanford C. Bernstein reissued a “market perform” rating and set a $45.00 price objective (down from $50.00) on shares of Sanofi in a research report on Thursday, February 8th. ValuEngine downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Nord/LB reissued a “neutral” rating on shares of Sanofi in a research report on Tuesday, January 2nd. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research report on Thursday, January 11th. Finally, Cowen set a $48.00 price objective on Sanofi and gave the stock a “hold” rating in a research report on Monday, December 18th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $49.33.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.